{
    "clinical_study": {
        "@rank": "28618", 
        "arm_group": {
            "arm_group_label": "Induction Chemotherapy", 
            "arm_group_type": "Experimental", 
            "description": "Cisplatin 75mg/m2 IV days 1, 15, 29; Docetaxel 75mg/m2 IV days 1, 15, 29; and Pegfilgrastim 6mg SC day 2, 16, 30"
        }, 
        "brief_summary": {
            "textblock": "Dose-dense chemotherapy is a chemotherapy treatment plan in which drugs are given with less\n      time between treatments than in standard chemotherapy.  The two chemotherapy drugs used in\n      this study, docetaxel and cisplatin, are approved for the treatment of lung cancer when\n      given every 21 days.  This study is exploring the response to chemotherapy when these drugs\n      are given every 14 days.   In addition, genetic tests will be performed on pre-treatment\n      specimens to identify signatures that may predict chemotherapy sensitivity or resistance."
        }, 
        "brief_title": "Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer", 
        "completion_date": {
            "#text": "January 2010", 
            "@type": "Actual"
        }, 
        "condition": "Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "All patients will receive induction chemotherapy with cisplatin  and docetaxel.\n      Pegfilgrastim will be administered approximately 24 hours following the end of the day 1\n      chemotherapy infusion.  Cycles will be repeated every 2 weeks for 3 cycles. Patients deemed\n      to be resectable will undergo surgical resection followed by postoperative thoracic\n      radiotherapy. Patients deemed inoperable will additionally receive concurrent\n      chemoradiotherapy. Response, using radiographic and/or pathologic means, will identify two\n      cohorts; responders and nonresponders.Gene expression profiling will then be performed on\n      pre-treatment specimens to identify signatures that predict for chemotherapy sensitivity or\n      resistance."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with documented stage III NSCLC (IIIA or IIIB, without malignant\n             pleural/pericardial effusion) are eligible for enrollment if they are considered\n             appropriate for treatment with chemotherapy, radiation, or surgery;\n\n          -  IIIA: T1-3 N2 M0, T3 N1 M0\n\n          -  IIIB: T4 N0-2 M0, T 1-4 N3 M0\n\n          -  Measurable or evaluable disease\n\n          -  Previously untreated with chemotherapy or radiotherapy for lung cancer;\n\n          -  No brain metastases;\n\n          -  No prior XRT\n\n          -  Performance status 0-2\n\n          -  \u226518 years of age\n\n          -  Informed Consent\n\n          -  Absolute neutrophil count (ANC) \u2265 1.5 x 109/L\n\n          -  Platelets \u2265 100 x 109/L\n\n          -  Bilirubin \u2264 1.5 x upper limit of normal for the institution (ULN)\n\n          -  SGOT and SGPT \u2264 2.5 x ULN for the institution\n\n          -  Creatinine \u2264 1.6 mg/dL\n\n          -  Hemoglobin \u2265 8.0 g/dL\n\n          -  Peripheral neuropathy \u2264 grade 1\n\n        Exclusion Criteria:\n\n          -  Known sensitivity to E. coli derived products (e.g. Filgrastim, HUMULIN\u00ae insulin,\n             L-asparaginase, HUMATROPE\u00ae Growth Hormone, INTRON\u00ae A);\n\n          -  Use of IV systemic antibiotics within 72 hours prior to chemotherapy;\n\n          -  Known HIV infection\n\n          -  Lithium or cytokines within 2 weeks prior of entry\n\n          -  Additional concurrent investigational drugs\n\n          -  History of myelodysplastic syndrome\n\n          -  Pregnant, nursing or having unprotected sex\n\n          -  Not available for follow-up assessment\n\n          -  Unable to comply with protocol procedures\n\n          -  Illnesses that may compromise ability to give informed consent.\n\n          -  Patients with a history of severe hypersensitivity reaction to Taxotere\u00ae or other\n             drugs formulated with polysorbate 80."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "13", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02157116", 
            "org_study_id": "Pro00004682"
        }, 
        "intervention": [
            {
                "arm_group_label": "Induction Chemotherapy", 
                "intervention_name": "cisplatin", 
                "intervention_type": "Drug", 
                "other_name": "Platinol"
            }, 
            {
                "arm_group_label": "Induction Chemotherapy", 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug", 
                "other_name": "Taxotere"
            }, 
            {
                "arm_group_label": "Induction Chemotherapy", 
                "intervention_name": "Pegfilgrastim", 
                "intervention_type": "Drug", 
                "other_name": "Neulasta"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Docetaxel", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Dose-Dense Chemotherapy", 
        "lastchanged_date": "June 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27710"
                }, 
                "name": "Duke University Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Dose-Dense Induction/Neoadjuvant Chemotherapy in the Treatment of Patients With Locally Advanced Non-Small Cell Lung Cancer With Additional Genomic Analyses to Identify Signatures Predictive of Chemotherapy Response.", 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Response will be assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.\tResponse is defined as the number patients with a Complete Response (CR), disappearance of all target lesions,  or a Partial Response (PR), at least a 30% decrease in the sum of the longest diameter (LD) of target lesions.", 
                "measure": "Induction Response", 
                "safety_issue": "No", 
                "time_frame": "Between 2 and 3 weeks after induction"
            }, 
            {
                "measure": "Differential gene expression between responsive and resistant tumor treated with dose-dense therapy", 
                "safety_issue": "No", 
                "time_frame": "at the end of the study, estimated 2.5 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02157116"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of Grade III/IV hematologic adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "During induction chemotherapy, approximately 6 weeks"
            }, 
            {
                "measure": "Number of Grade III/IV non-hematologic adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "During induction chemotherapy, approximately 6 weeks"
            }, 
            {
                "measure": "Number of patients who were able to maintain Hemoglobin between 11-13 g/dL during induction", 
                "safety_issue": "Yes", 
                "time_frame": "During induction, approximately 6 weeks"
            }, 
            {
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "Approximately 10 years"
            }
        ], 
        "source": "Duke University", 
        "sponsors": {
            "collaborator": {
                "agency": "Sanofi-Aventis Pharmaceuticals, Inc.", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2006", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014", 
        "why_stopped": "Insufficient accrual to meet analysis goals"
    }
}